Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151987 | 1.00 | HTR2C (0.56) | HTR2CHTR2AHTR2BDYRK1AKCNH2 | |
| SCHEMBL905950 | 1.00 | HTR2C (0.56) | HTR2CHTR2AHTR2BDYRK1AKCNH2 | |
| SCHEMBL905894 | 0.90 | HTR2C (0.59) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL905864 | 0.90 | HTR2C (0.59) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL906013 | 0.90 | HTR2C (0.59) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025613 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025610 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| Hydrochloric Acid SCHEMBL6025608 | 0.88 | HTR2C (0.58) | HTR2CHTR2AHTR2BPTGDR2HTR6 | |
| SCHEMBL10249290 | 0.76 | HTR2C (0.69) | HTR2CHTR2AKCNH2HTR6CYP1A2 | |
| SCHEMBL18202157 | 0.76 | HTR2C (0.41) | HTR2CHTR2ADYRK1ANFATC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | claimed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | claimed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | HTR2C 410/4885HTR2A 488/4885HTR2B 470/4885 |
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.